Nerium Biotechnology, Inc.

May 02, 2014 16:09 ET

Nerium Corporate Update

SAN ANTONIO, TEXAS--(Marketwired - May 2, 2014) - Nerium Biotechnology, Inc. ("NBI") wishes to announce that its Board of Directors has met and made the following resolutions:

  • Mr. Richard Boxer of Toronto, Canada has been appointed as a director of NBI and the number of directors has been increased from six to seven. Mr. Boxer has extensive experience with business and community organizations in both the "for profit" and "not for profit" sectors and has served in numerous capacities on various boards and committees. He has expertise in complex political, regulatory and compliance environments dealing with securities, licenses and labour in Canada. Mr. Boxer has extensive knowledge of Canadian equity and debt markets for both private and public markets and is currently the President of Buckingham Capital Corporation, a small privately owned Canadian merchant bank. Mr. Boxer was granted 50,000 options under NBI's incentive stock option plan (the "Plan"). Each option entitles the holder to acquire one common share of NBI at the price of US$2.00 per share until April 28, 2024 and is subject to the terms of the Plan and any necessary regulatory and stock exchange approvals.

  • NBI will withdraw its application to the Ontario Securities Commission seeking a ruling that it cease to be a reporting issuer. The application was announced in the NBI's press release dated February 25, 2014.

  • The annual meeting of shareholders has been scheduled for June 25, 2014 and the record date for determining shareholders entitled to vote at the meeting has been set at May 9, 2014. In accordance with the new by-laws of NBI approved at the last annual meeting of shareholders, NBI will utilize the Notice and Access process for delivering shareholder meeting materials. Under Notice and Access, NBI will deliver proxy-related materials by: (i) posting the information circular and other related materials on a non-SEDAR website; and (ii) delivering a notice advising the shareholders that the proxy related materials are available on the website and how they will be able to access the materials. A form of proxy will also be included in the Notice and Access package.

  • The audited annual financial statements and the annual Management Discussion and Analysis for the year ended December 31, 2013 were approved and filed with the NBI's documents on SEDAR (www.sedar.com).

About Nerium Biotechnology, Inc.

NBI is a biotechnology company involved in the research, product development, manufacture and marketing of Nerium oleander-based products. Our existing product line includes Anvirzel™, NeriumAD® (Day Cream and Night Cream) and the recently introduced NeriumFirm™, a contour cream.

For many years, the Company was dependent on oleander biomass from a third party grower. During 2013, the Company began to take steps to further enhance quality control at the farm level by purchasing the farming operations. The Company now owns the land and the plants grown to produce the biomass that is used in making of the oleander based extracts.

NeriumAD (night cream) is a cosmetic product designed for use on wrinkled and/or aging skin. A companion product is the NeriumAD™ Day Cream. These products were developed by our wholly-owned subsidiary, Nerium SkinCare, Inc. ("NSC") and are manufactured for NSC by third party companies. The products are then marketed by Nerium International, LLC ("NI") based in Dallas, Texas. The third skincare product, NeriumFirm™, is being introduced in second quarter of 2014.

The Company is a reporting issuer in good standing in the Province of Ontario whose shares are not listed on any stock exchange or quotation system. There are 36,006,681 common shares issued and outstanding.

Contact Information

  • Nerium Biotechnology, Inc.
    Joseph B. Nester
    CFO
    210-822-7908

    Nerium Biotechnology, Inc.
    Dennis R. Knocke
    President and CEO
    210-822-7908